Diagnosis and management of lipid disorders

Clinics in Family Practice

Volumn 3, Issue 4, 2001, Pages 757-780

  Heidelbaugh, Joel J ^a,b   Rion, Raymond J ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Ypsilanti Health Center   (United States)

^c Dexter Family Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; AVASIMIBE; BILE ACID; C REACTIVE PROTEIN; CERIVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIGITALIS; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITARVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NK 107; PHENYLBUTAZONE; PRAVASTATIN; PROPRANOLOL; ROSUVASTATIN; SCH 59325; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CAREGIVER; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIET THERAPY; DRUG POTENCY; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MALE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; RHABDOMYOLYSIS; SCREENING TEST; SECONDARY PREVENTION; SMOKING CESSATION; THROMBOEMBOLISM; WEIGHT REDUCTION;

EID: 0035714125     PISSN: 15225720     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1522-5720(05)70099-4     Document Type: Article

References (57)

1. Apolipoproteins and lipoproteins
2. Immunochemical quantification of human plasma Lp(a) lipoprotein
3. XIIth International Symposium on Atherosclerosis
4. Dietary fat and risk of coronary heart disease in men: Cohort follow-up study in the United States
5. Lipids and dyslipoproteinemia
6. Plasma high-density lipoprotein cholesterol concentrations determined after removal of other lipoproteins by heparin/manganese precipitation or by ultracentrifugation
7. Lp(a) phenotypes, other lipoprotein parameters and family history of heart disease in middle aged males
8. Treatment of common lipoprotein disorders
9. The multiple risk factor intervention trial (MRFIT): IV. Intervention on blood lipids
10. Lipoprotein cholesterol concentrations in plasma of human subjects as measured in the fed and fasted states
11. Plasma triglyceride level and mortality from coronary heart disease
12. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
13. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in post-menopausal women
14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
15. Statement on exercise: Benefits and recommendations for physical activity programs for all Americans
16. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group
17. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge
18. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines
19. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
20. Primary prevention of coronary heart disease: Integrating risk assessment with intervention
21. Fibric acids: Effects on lipids and lipoprotein metabolism
22. Lipoprotein biosynthesis and metabolism
23. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
24. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) research group
25. Long term effects of water soluble dietary fiber in the management of hypercholesterolemia in healthy men and women
26. Statins and the risk of dementia
27. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
28. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable and chronic angina pectoris: The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group
29. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
30. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease (CHD) and a broad levels
31. Cholesterol and coronary heart disease: The importance of patient-specific attributable risk
32. HMG-CoA reductase inhibitors and the risk of fractures
33. Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-1 and E in normolipidemic smoking men: Relations with lipid transfer proteins and LCAT activities
34. Reduction of serum cholesterol with sitostanolester margarine in a mildly hypercholesterolemic population
35. Normal variation of plasma lipoprotein: Postural effects on plasma concentrations of lipids, lipoproteins, and apolipoproteins
36. Stimulation of bone formation in vitro and in rodents by statins
37. National Diet-Heart Study Research Group: The national diet-heart study final report
38. Relationship of serum lipid concentrations to alcohol consumption
39. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treatment Investigators
40. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous-vein grafts
41. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy
42. Measurement of C-Reactive Protein for the targeting of statin therapy in the primary prevention of acute coronary events
43. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Interventional Trial Study Group
44. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE)
45. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia
46. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S)
47. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
48. Fish consumption, fish oil, lipids, and coronary heart disease
49. Screening for high blood cholesterol and other lipid abnormalities
50. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
51. The effects of plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women